Welcome to our dedicated page for Celldex Therapeutics SEC filings (Ticker: CLDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Celldex Therapeutics, Inc. (NASDAQ: CLDX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Celldex is a biopharmaceutical company focused on antibody-based therapies in immunology, and its filings offer detailed information on clinical programs, financial position and material events affecting the business.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports for discussions of Celldex’s pipeline, including barzolvolimab in chronic spontaneous urticaria (CSU), cold urticaria (ColdU), symptomatic dermographism (SD), prurigo nodularis (PN) and atopic dermatitis (AD), as well as the bispecific antibody CDX-622. These reports typically describe the company’s focus on mast cell biology, key risk factors, research and development spending and overall operating results.
Form 8-K current reports capture material events such as clinical trial readouts and financial updates. Recent examples include 8-K filings referencing topline Phase 2 results for barzolvolimab in eosinophilic esophagitis (EoE) and quarterly financial results press releases. These documents help readers track how new data and business developments are communicated to regulators and the market.
Through Stock Titan, users can also access Section 16 filings such as Form 4, where available, to monitor insider transactions in CLDX common stock, and proxy-related filings that discuss governance and executive matters. AI-powered summaries on this page are designed to explain the key points of lengthy filings, highlight clinically and financially relevant sections, and make it easier to compare updates over time.
All filings are sourced directly from EDGAR and updated as new documents are submitted, giving investors, analysts and researchers a structured view of Celldex’s regulatory history and ongoing disclosure around its immunology-focused programs.
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on mast cell biology, developing monoclonal and bispecific antibodies for severe inflammatory, allergic and autoimmune diseases. Its lead drug, barzolvolimab (CDX‑0159), targets the KIT receptor to inhibit and deplete mast cells, aiming to treat conditions where current therapies are inadequate.
Barzolvolimab has shown rapid, durable and clinically meaningful Phase 1/2 results in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), and is now in large global Phase 3 programs in CSU and Phase 3 in cold urticaria and symptomatic dermographism, plus Phase 2 trials in prurigo nodularis and atopic dermatitis. Celldex discontinued eosinophilic esophagitis after mast cell depletion did not translate into symptom benefit but is advancing CDX‑622, a bispecific targeting TSLP and SCF, through Phase 1. The company is scaling up commercial manufacturing, building its commercial organization, and relies on key licenses such as a Yale agreement for barzolvolimab, while operating in a highly competitive dermatology and immunology landscape. As of June 30, 2025, the aggregate market value of common stock held by non‑affiliates was $1.3 billion, with 66,566,346 shares outstanding as of February 13, 2026.
Celldex Therapeutics reported wider losses for the fourth quarter and full year 2025 as it accelerated investment in its immunology pipeline, led by barzolvolimab in chronic urticarias. Fourth quarter revenue was
The company posted a fourth quarter net loss of
Operationally, Celldex completed enrollment in both Phase 3 chronic spontaneous urticaria studies six months ahead of guidance, with topline data expected in Q4
Celldex Therapeutics, Inc. shareholder Wellington Management Group LLP and affiliated entities report beneficial ownership of 8,079,608 shares of common stock, representing 12.16% of the class. The shares are held of record by clients of various Wellington investment advisers, including Vanguard Health Care Fund.
The Wellington entities report no sole voting or dispositive power and instead share voting and/or dispositive power over these shares through their advisory relationships. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Celldex.
State Street Corporation filed a Schedule 13G reporting a passive ownership stake in Celldex Therapeutics, Inc. common stock. As of 12/31/2025, State Street reported beneficial ownership of 3,397,713 shares, representing 5.1% of Celldex’s outstanding common stock.
State Street reported shared voting power over 3,194,178 shares and shared dispositive power over 3,397,713 shares, with no sole voting or dispositive authority. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of Celldex.
Celldex Therapeutics senior executive reports stock option exercises. A company officer serving as Senior Vice President and Chief Business Officer filed a Form 4 covering two option exercises in Celldex Therapeutics, Inc. common stock on 12/15/2025. The reporting person acquired 8,333 shares at an exercise price of $9.0165 per share and 11,000 shares at an exercise price of $2.78 per share through the exercise of incentive stock options.
Following these transactions, the officer beneficially owns 20,097 shares of Celldex common stock directly, which includes 764 shares acquired under the company’s 2004 Employee Stock Purchase Plan. After the exercises, one option grant for 8,333 shares expiring on 06/13/2028 remains partially outstanding with 5,000 derivative securities beneficially owned, while a second option grant for 11,000 shares expiring on 06/19/2029 has been fully exercised.
Celldex Therapeutics officer Freddy A. Jimenez reported selling 4,166 shares of Celldex Therapeutics, Inc. common stock on December 4, 2025 at $29.095 per share. Following this sale, he directly owns 30,796 shares. The report identifies him as the company’s Senior Vice President and General Counsel and indicates the Form 4 was filed for a single reporting person.
Celldex Therapeutics (CLDX) filed a Form 4 reporting option exercises and a share sale by an insider. On 11/13/2025, the reporting person exercised three incentive stock options for 6,876 shares at $9.0165, 26,672 shares at $10.38, and 15,750 shares at $22.48, receiving common stock in each case. On the same date, they sold 49,298 common shares at a weighted average price of $24.0005 per share, with trades executed between $24.00 and $24.05. After these transactions, the insider directly owned 20,833 common shares and held 7,875 derivative securities (options) directly.
Celldex Therapeutics (CLDX) reported a Form 4 for its SVP & Chief Commercial Officer, noting the grant of 100,000 stock options on 11/10/2025 under the company’s 2021 Omnibus Equity Incentive Plan at an exercise price of
The filing states 25% of the award vests on
Celldex Therapeutics (CLDX) filed a Form 3, the initial statement of beneficial ownership for a company insider. The reporting person is Teri Lawver, who serves as SVP & Chief Commercial Officer. The filing states that no securities are beneficially owned by the reporting person.
The date of event is 11/10/2025, and the form was filed on an individual basis. The document was signed by /s/ Sam Martin, attorney-in-fact for Teri Lawver on 11/12/2025.
Celldex Therapeutics (CLDX) filed its Q3 2025 10-Q, reporting no revenue for the quarter and higher operating spend as clinical programs advanced. For the three months ended September 30, 2025, operating expenses were $73.6 million and the company recorded a net loss of $67.0 million (vs. $42.1 million a year ago). For the nine months, operating expenses were $201.6 million with a net loss of $177.4 million.
Liquidity remains strong: as of September 30, 2025, cash, cash equivalents and marketable securities totaled $583.2 million. Net cash used in operating activities was $147.0 million for the nine months. Management states these resources are expected to fund operations for at least the next twelve months from issuance. R&D spend is led by the barzolvolimab (anti‑KIT) program, which accounted for $133.97 million of R&D in the nine-month period; CDX‑622 and other programs accounted for the balance. An at‑the‑market facility with $300.0 million registered capacity remained unsold at quarter end. Common shares outstanding were 66,446,846 at September 30, 2025.